3/21
06:20 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) was upgraded by analysts at B. Riley to a "strong-buy" rating.
3/20
08:05 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at B. Riley. They set a "buy" rating and a $37.00 price target on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at B. Riley. They set a "buy" rating and a $37.00 price target on the stock.
3/19
08:07 pm
avbp
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts [Yahoo! Finance]
Low
Report
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts [Yahoo! Finance]
3/10
07:21 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is now covered by analysts at Guggenheim. They set a "buy" rating and a $45.00 price target on the stock.
3/7
08:12 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
3/3
07:42 am
avbp
ArriVent BioPharma Reports Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
ArriVent BioPharma Reports Full Year 2024 Financial Results [Yahoo! Finance]
3/3
07:00 am
avbp
ArriVent BioPharma Reports Full Year 2024 Financial Results
Medium
Report
ArriVent BioPharma Reports Full Year 2024 Financial Results
1/22
08:14 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $36.00 to $39.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $36.00 to $39.00. They now have a "buy" rating on the stock.
1/21
08:21 pm
avbp
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers [Yahoo! Finance]
Medium
Report
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers [Yahoo! Finance]
1/21
07:00 pm
avbp
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
Medium
Report
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers